Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence - PubMed (original) (raw)
Clinical Trial
Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence
Helena Vorma et al. Subst Use Misuse. 2005.
Abstract
We described characteristics of subjects with benzodiazepine dependence that was typically complicated by harmful and hazardous alcohol use or high benzodiazepine doses, and assessed predictors of successful discontinuation of benzodiazepines for this group. Seventy-six patients who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were assessed. The trial was conducted between February 1995 and July 1999. The mean age +/- SD of subjects was 40.0 +/- 9.6 years, 55% were male, 38% were married or cohabiting, and 70% had received more than nine years of education. The median benzodiazepine dose was 35 mg/day (range 2.5-180) in diazepam equivalents. The median duration of benzodiazepine use was 84 (range 8-360) months. Subjects with lower benzodiazepine doses and no previous withdrawal attempts were more successful at benzodiazepine discontinuation. Cluster B personality/borderline personality disorder was associated with an inability to stop benzodiazepine use and with "dropping out" of treatment. Alcohol use-related disorders or other psychiatric diagnoses were not associated with outcome. Further studies on predictors of successful benzodiazepine discontinuation in different populations are required. Patients manifesting cluster B personality/borderline personality disorder and benzodiazepine dependence may need concomitant treatment for their personality disorders to benefit from benzodiazepine discontinuation treatment.
Similar articles
- [Alcohol-dependent patients with benzodiazepine abuse: its relation to personality disorders and neuropsychological impairment].
Monràs M, Mondón S, Jou J. Monràs M, et al. Med Clin (Barc). 2008 May 17;130(18):693-5. doi: 10.1157/13120771. Med Clin (Barc). 2008. PMID: 18501140 Spanish. - Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation.
Rickels K, Schweizer E, Case WG, Greenblatt DJ. Rickels K, et al. Arch Gen Psychiatry. 1990 Oct;47(10):899-907. doi: 10.1001/archpsyc.1990.01810220015002. Arch Gen Psychiatry. 1990. PMID: 2222129 Clinical Trial. - Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence.
Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Vorma H, et al. Addict Behav. 2004 Aug;29(6):1059-65. doi: 10.1016/j.addbeh.2004.03.003. Addict Behav. 2004. PMID: 15236807 Clinical Trial. - Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings.
Denis C, Fatséas M, Lavie E, Auriacombe M. Denis C, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005194. doi: 10.1002/14651858.CD005194.pub2. Cochrane Database Syst Rev. 2006. PMID: 16856084 Updated. Review. - [Abuse of alcohol and benzodiazepine during substitution therapy in heroin addicts: a review of the literature].
Laqueille X, Launay C, Dervaux A, Kanit M. Laqueille X, et al. Encephale. 2009 Jun;35(3):220-5. doi: 10.1016/j.encep.2008.05.005. Epub 2008 Oct 1. Encephale. 2009. PMID: 19540407 Review. French.
Cited by
- Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases.
Tennant M, Frampton C, Mulder R, Beaglehole B. Tennant M, et al. BJPsych Open. 2023 Oct 26;9(6):e200. doi: 10.1192/bjo.2023.592. BJPsych Open. 2023. PMID: 37881020 Free PMC article. - Benzodiazepines: Uses, Dangers, and Clinical Considerations.
Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, Cornett EM, Kaye AM, Kaye AD. Edinoff AN, et al. Neurol Int. 2021 Nov 10;13(4):594-607. doi: 10.3390/neurolint13040059. Neurol Int. 2021. PMID: 34842811 Free PMC article. Review. - Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders.
Chapoutot M, Peter-Derex L, Bastuji H, Leslie W, Schoendorff B, Heinzer R, Siclari F, Nicolas A, Lemoine P, Higgins S, Bourgeois A, Vallet GT, Anders R, Ounnoughene M, Spencer J, Meloni F, Putois B. Chapoutot M, et al. Int J Environ Res Public Health. 2021 Sep 28;18(19):10222. doi: 10.3390/ijerph181910222. Int J Environ Res Public Health. 2021. PMID: 34639523 Free PMC article. Review. - Psychosocial interventions for benzodiazepine harmful use, abuse or dependence.
Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Darker CD, et al. Cochrane Database Syst Rev. 2015;2015(5):CD009652. doi: 10.1002/14651858.CD009652.pub2. Cochrane Database Syst Rev. 2015. PMID: 26106751 Free PMC article. Review. - Medications in the treatment of borderline personality disorder 2006.
Mercer D. Mercer D. Curr Psychiatry Rep. 2007 Feb;9(1):53-62. doi: 10.1007/s11920-007-0010-1. Curr Psychiatry Rep. 2007. PMID: 17257515 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical